Withings announced it is taking a significant step toward reshaping preventative healthcare. Backed with €20.7 million (about $22.5 million) investment and support from the French government through the France 2030 initiative, the company is launching Project DEEP (DEvice as a hEalth Prevention platform). This initiative aims to utilize AI and medical device innovation to advance early detection and prevention of cardiometabolic diseases and accelerate the digital and prevention transition of healthcare systems worldwide.
Project DEEP represents a significant milestone in the fight against the global rise of cardiometabolic diseases. And these conditions, including diabetes, hypertension, atrial fibrillation, and neuropathies, significantly strain healthcare systems. By focusing on early detection and prevention, Withings looks to address these challenges before they lead to serious complications such as stroke, myocardial infarction, and amputations.
This DEEP project is positioned to develop advanced and noninvasive medical devices capable of detecting cardiometabolic pathologies earlier, improving the quality of life for millions and significantly reducing healthcare costs. These solutions align perfectly with the goals of France 2030, a €54 billion (about $56.6 billion) initiative dedicated to shaping France’s sustainable and innovative future.
Withings already provides a solid portfolio of connected medical devices, including smart scales, blood pressure monitors, watches, sleep analyzers, and urine analyzers. These devices measure over 50 clinically validated cardiometabolic biomarkers in noninvasive, home-based settings. Combining AI with this ecosystem, Withings enables scalable, proactive care tailored to individual health profiles.
The company’s commitment to innovation is backed by its entirely French-based R&D operations, 128 clinical studies, and over 12 billion collected health measurements. These resources, combined with a strong network of medical partners and 10 million users, position Withings as a cornerstone of the global digital health ecosystem.
Withings aims to redefine how healthcare systems address chronic diseases by utilizing technological breakthroughs, AI, and strategic partnerships. And the DEEP project underscores Withings’ leadership in preventative care, strengthening its role as a French and global leader in digital health.
This initiative highlights the potential of public-private collaboration to create a future where technology extends healthy lifespans, reduces healthcare costs, and improves lives worldwide.
KEY QUOTES:
“With the surge in cardiometabolic diseases burdening healthcare systems, technological innovation and AI research are pivotal in transitioning to a preventive care model. France 2030’s support underscores the importance of empowering French companies like Withings to lead globally in this transformation. Over the next five years, Project DEEP will spearhead Withings’ R&D efforts, enhancing our existing products and paving the way for groundbreaking medical devices and solutions we have yet to imagine.”
- Eric Carreel, Chairman and Founder of Withings
“Technological innovation and AI research are essential for transitioning from a curative to a preventive healthcare model. Early detection must extend healthy lifespans and enhance the quality of life for patients globally. Project DEEP exemplifies this vision by integrating innovation into our healthcare systems.”
- Lise Alter, Director of the Health Innovation Agency (Agence de l’Innovation en Santé) who highlights Project DEEP as a key initiative aligned with France 2030’s mission
